alexa Endogenous Laser Induced Ventricular Enhancement (ELIVE
ISSN: 2157-7633

Journal of Stem Cell Research & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Short Communication

Endogenous Laser Induced Ventricular Enhancement (ELIVE™) Therapy: A New Paradigm for Treating Heart Failure?

Michael Heke1,3* and Hans-Michael Klein2,3*

1Laboratory of Stem Cell Biology and Molecular Embryology, The Rockefeller University, New York, USA

2Department of Cardiovascular Surgery, Heinrich Heine University, Medical Faculty, Duesseldorf, Germany

3Elive Medical Ltd., Dublin, Ireland

*Corresponding Author:
Prof. Dr. med. Hans-Michael Klein
Department of Cardiovascular Surgery
Heinrich Heine University, Medical Faculty
Moorenstr. 5D – 40225 Duesseldorf, Germany
Tel: +49-211-81-18331
Fax: +49-211-81-18333
E-mail: [email protected]

Michael Heke, Ph.D.
Laboratory of Stem Cell Biology and Molecular Embryology
The Rockefeller University, 1230 York Avenue
Box 32 New York, NY 10065, USA
Tel: +1-212-327-8655
Fax: +1-212-327-8685
E-mail: [email protected]

Received date: May 29, 2014; Accepted date: September 23, 2014; Published date: September 25, 2014

Citation: Heke M, Klein HM (2014) Endogenous Laser Induced Ventricular Enhancement (ELIVE™) Therapy: A New Paradigm for Treating Heart Failure? J Stem Cell Res Ther 4:236. doi:10.4172/2157-7633.1000236

Copyright: © 2014 Heke M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



 

Abstract

Endogenous Laser Induced Ventricular Enhancement (ELIVE™) therapy is an innovative approach of treating heart failure, evolved from the results achieved in a clinical trial that assessed safety and feasibility of laser-supported CD133pos intramyocardial cell transplantation in patients suffering from ischemic cardiomyopathy. This study demonstrated significant restoration potential of hibernating myocardium upon autologous, bone marrow-derived cell transplantation when supported by low-energy laser treatment. ELIVE™ therapy now employs a new generation of laser, featuring a hollow fiber waveguide, rendering this approach amenable for a minimally invasive procedure, in combination with a preceding granulocyte colony stimulating factor (GCSF) treatment of the patient in order to mobilize endogenous stem and progenitor cells. The rationale of this new therapy is for the patient himself to become his own ‘bioreactor’, effectively triggering and amplifying endogenous regeneration mechanisms based on autologous stem and progenitor cells.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords